Twilio Inc vs Zimmer Biomet Holdings Inc — how do they compare? Twilio Inc trades at $281.82 (market cap $42.35B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: Twilio Inc is far larger — about 2.5× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twilio Inc for 56 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TWLO | ZBH | |
|---|---|---|
Market Cap | $42.35B | $16.95B |
Volume | 1,862,642 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $301.27 | $103.98 |
52-Week Low | $106.23 | $79.58 |
Typical Hold Time | 56 Days | 89 Days |
Enterprise Value | $40.76B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $273.00, down 2.64% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $5.07 billion in 2025, turning profitable with a net income of $33.83 million, and has beaten EPS estimates for three consecutive quarters. Recent inclusion in the S&P 500 index and positive analyst sentiment highlight its market position.
Outlook remains positive driven by accelerating revenue growth and Voice AI expansion, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with a $254.65 price target, though recent insider selling and a high P/E of 38.09 warrant caution for value-focused investors.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →